echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Chloroquine/hydroxychloroquine: an inflamma inhibitor in severe COVID-19?

    Chloroquine/hydroxychloroquine: an inflamma inhibitor in severe COVID-19?

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chloroquine (CQ) and hydroxychloroquine (HCQ) are in the aminoquinoline class


    Effects of CQ and HCQ on activation of NLRP3 inflammasomes:

    In one study, researchers investigated how chloroquine inhibited activation of the NLRP3 inflammasome and protected mice from endotoxin shock


    Both artemisinin and hydroxychloroquine have anti-inflammatory and immunomodulatory activities


    To study the effects of hydroxychloroquine on NLRP3 inflammatory bodies, serum amyloid A (SAA) was used to stimulate human neutrophils and the secretion


    Other drugs that inhibit the NLRP3 inflammatory body:

    CQ and HCQ were the most important and certainly the most challenging drugs in the treatment of COVID-19 in the study, but a range of drugs, including statins, antivirals, interferons, antiallergic compounds, and immunomodulators, are currently being used in clinical trials


    Taken together, hundreds of clinical trials are being conducted in different countries to investigate potential treatments for


     

    References: Bahadoram M, Keikhaei B, Saeedi-Boroujeni A, Mahmoudian-Sani MR.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.